MK Proteins Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 12, 2025, 11:48 am

Quick Insight

MK Proteins Ltd, operating in the Edible Oils & Solvent Extraction industry, presents a mixed financial picture. With a current share price of 6.92 and a market cap of 257 Cr., the P/E ratio stands at 27.3, indicating a moderately valued stock. While the ROE and ROCE are respectable at 12.4% and 12.9% respectively, the OPM of 4.79% raises concerns about operational efficiency. The company's high P/BV ratio of 6.07x suggests an overvalued position, while the healthy ICR of 16.02x provides some solace amidst the 39 Cr. in borrowings. Shareholders, primarily promoters at 74.82%, should closely monitor the CCC of 142 days. In conclusion, MK Proteins Ltd exhibits strengths in profitability metrics but faces challenges in operational margins and leverage management, warranting a balanced investment approach.

Competitors of MK Proteins Ltd

All Competitor Stocks of MK Proteins Ltd

Quarterly Result

Last Updated: August 20, 2025, 7:35 am

Below is a detailed analysis of the quarterly data for MK Proteins Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 114.95 Cr.. The value appears to be declining and may need further review. It has decreased from 137.20 Cr. (Mar 2025) to 114.95 Cr., marking a decrease of 22.25 Cr..
• For Expenses, as of Jun 2025, the value is 109.44 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 132.55 Cr. (Mar 2025) to 109.44 Cr., marking a decrease of 23.11 Cr..
• For Operating Profit, as of Jun 2025, the value is 5.51 Cr.. The value appears strong and on an upward trend. It has increased from 4.65 Cr. (Mar 2025) to 5.51 Cr., marking an increase of 0.86 Cr..
• For OPM %, as of Jun 2025, the value is 4.79%. The value appears strong and on an upward trend. It has increased from 3.39% (Mar 2025) to 4.79%, marking an increase of 1.40%.
• For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.02 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.02 Cr..
• For Interest, as of Jun 2025, the value is 0.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.67 Cr. (Mar 2025) to 0.70 Cr., marking an increase of 0.03 Cr..
• For Depreciation, as of Jun 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.01 Cr..
• For Profit before tax, as of Jun 2025, the value is 4.71 Cr.. The value appears strong and on an upward trend. It has increased from 3.91 Cr. (Mar 2025) to 4.71 Cr., marking an increase of 0.80 Cr..
• For Tax %, as of Jun 2025, the value is 25.27%. The value appears to be improving (decreasing) as expected. It has decreased from 28.64% (Mar 2025) to 25.27%, marking a decrease of 3.37%.
• For Net Profit, as of Jun 2025, the value is 3.51 Cr.. The value appears strong and on an upward trend. It has increased from 2.80 Cr. (Mar 2025) to 3.51 Cr., marking an increase of 0.71 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.09. The value appears strong and on an upward trend. It has increased from 0.07 (Mar 2025) to 0.09, marking an increase of 0.02.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:54 pm

Growth

Last Updated: September 5, 2025, 10:00 am

Balance Sheet

Last Updated: June 16, 2025, 11:46 am

Below is a detailed analysis of the balance sheet data for MK Proteins Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 38.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 38.00 Cr..
• For Reserves, as of Mar 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2024) to 32.00 Cr., marking an increase of 8.00 Cr..
• For Borrowings, as of Mar 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 20.00 Cr. (Mar 2024) to 39.00 Cr., marking an increase of 19.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 7.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 131.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 96.00 Cr. (Mar 2024) to 131.00 Cr., marking an increase of 35.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 1.00 Cr..
• For CWIP, as of Mar 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2024) to 7.00 Cr., marking an increase of 1.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 88.00 Cr. (Mar 2024) to 120.00 Cr., marking an increase of 32.00 Cr..
• For Total Assets, as of Mar 2025, the value is 131.00 Cr.. The value appears strong and on an upward trend. It has increased from 96.00 Cr. (Mar 2024) to 131.00 Cr., marking an increase of 35.00 Cr..

However, the Borrowings (39.00 Cr.) are higher than the Reserves (32.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for MK Proteins Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. It has decreased from 10.00 (Mar 23) to 1.00, marking a decrease of 9.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 0.30. This value is below the healthy minimum of 5. It has decreased from 8.51 (Mar 23) to 0.30, marking a decrease of 8.21.
• For Diluted EPS (Rs.), as of Mar 24, the value is 0.30. This value is below the healthy minimum of 5. It has decreased from 8.51 (Mar 23) to 0.30, marking a decrease of 8.21.
• For Cash EPS (Rs.), as of Mar 24, the value is 0.31. This value is below the healthy minimum of 3. It has decreased from 9.11 (Mar 23) to 0.31, marking a decrease of 8.80.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 1.63. It has decreased from 40.18 (Mar 23) to 1.63, marking a decrease of 38.55.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 1.63. It has decreased from 40.18 (Mar 23) to 1.63, marking a decrease of 38.55.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 6.54. It has decreased from 251.64 (Mar 23) to 6.54, marking a decrease of 245.10.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 0.45. This value is below the healthy minimum of 2. It has decreased from 13.66 (Mar 23) to 0.45, marking a decrease of 13.21.
• For PBIT / Share (Rs.), as of Mar 24, the value is 0.44. This value is within the healthy range. It has decreased from 13.06 (Mar 23) to 0.44, marking a decrease of 12.62.
• For PBT / Share (Rs.), as of Mar 24, the value is 0.41. This value is within the healthy range. It has decreased from 11.67 (Mar 23) to 0.41, marking a decrease of 11.26.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 0.29. This value is below the healthy minimum of 2. It has decreased from 8.51 (Mar 23) to 0.29, marking a decrease of 8.22.
• For PBDIT Margin (%), as of Mar 24, the value is 6.94. This value is below the healthy minimum of 10. It has increased from 5.42 (Mar 23) to 6.94, marking an increase of 1.52.
• For PBIT Margin (%), as of Mar 24, the value is 6.73. This value is below the healthy minimum of 10. It has increased from 5.18 (Mar 23) to 6.73, marking an increase of 1.55.
• For PBT Margin (%), as of Mar 24, the value is 6.29. This value is below the healthy minimum of 10. It has increased from 4.63 (Mar 23) to 6.29, marking an increase of 1.66.
• For Net Profit Margin (%), as of Mar 24, the value is 4.56. This value is below the healthy minimum of 5. It has increased from 3.38 (Mar 23) to 4.56, marking an increase of 1.18.
• For Return on Networth / Equity (%), as of Mar 24, the value is 18.35. This value is within the healthy range. It has decreased from 21.17 (Mar 23) to 18.35, marking a decrease of 2.82.
• For Return on Capital Employeed (%), as of Mar 24, the value is 26.54. This value is within the healthy range. It has decreased from 30.87 (Mar 23) to 26.54, marking a decrease of 4.33.
• For Return On Assets (%), as of Mar 24, the value is 11.64. This value is within the healthy range. It has increased from 10.14 (Mar 23) to 11.64, marking an increase of 1.50.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.05 (Mar 23) to 0.00, marking a decrease of 0.05.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.31. This value is within the healthy range. It has decreased from 0.88 (Mar 23) to 0.31, marking a decrease of 0.57.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 2.44. It has decreased from 3.30 (Mar 23) to 2.44, marking a decrease of 0.86.
• For Current Ratio (X), as of Mar 24, the value is 2.53. This value is within the healthy range. It has increased from 1.96 (Mar 23) to 2.53, marking an increase of 0.57.
• For Quick Ratio (X), as of Mar 24, the value is 0.19. This value is below the healthy minimum of 1. It has decreased from 0.58 (Mar 23) to 0.19, marking a decrease of 0.39.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.73. This value is below the healthy minimum of 4. It has decreased from 4.23 (Mar 23) to 2.73, marking a decrease of 1.50.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 16.02. This value is within the healthy range. It has increased from 9.86 (Mar 23) to 16.02, marking an increase of 6.16.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 11.53. This value is within the healthy range. It has increased from 7.14 (Mar 23) to 11.53, marking an increase of 4.39.
• For Enterprise Value (Cr.), as of Mar 24, the value is 389.87. It has decreased from 957.87 (Mar 23) to 389.87, marking a decrease of 568.00.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.59. This value is within the healthy range. It has decreased from 3.04 (Mar 23) to 1.59, marking a decrease of 1.45.
• For EV / EBITDA (X), as of Mar 24, the value is 22.85. This value exceeds the healthy maximum of 15. It has decreased from 56.03 (Mar 23) to 22.85, marking a decrease of 33.18.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.51. This value is within the healthy range. It has decreased from 2.90 (Mar 23) to 1.51, marking a decrease of 1.39.
• For Price / BV (X), as of Mar 24, the value is 6.07. This value exceeds the healthy maximum of 3. It has decreased from 18.17 (Mar 23) to 6.07, marking a decrease of 12.10.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.51. This value is within the healthy range. It has decreased from 2.90 (Mar 23) to 1.51, marking a decrease of 1.39.
• For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 23) to 0.03, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness